Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 11, 2012 | December 13, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | February 25, 2022 | March 01, 2022 |
| CrowdStrike Holdings, Inc.CRWD · Entity 1172 | Director | September 18, 2026 | September 22, 2026 |
| GENERAL DYNAMICS CORPGD · Entity 2916 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 11, 2012 · Filed December 13, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 179,338 |
Ending reported balance
After 2012-12-11 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2012-12-11 · Exercise / conversion · Acquired 36,985 · Balance 216,323 Row 2 · 2012-12-11 · Exercise / conversion · Acquired 67,200 · Balance 283,523 Row 3 · 2012-12-11 · Exercise / conversion · Acquired 1,045 · Balance 284,568 Row 4 · 2012-12-11 · Exercise / conversion · Acquired 2,395 · Balance 286,963 Row 5 · 2012-12-11 · Exercise / conversion · Acquired 652 · Balance 287,615 Row 6 · 2012-12-11 · Exercise / conversion · Acquired 11,500 · Balance 299,115 Row 7 · 2012-12-11 · Sale · Disposed 119,777 · Balance 179,338 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.34 · Expires 2015-02-17 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2012-12-11 · Exercise / conversion · Disposed 36,985 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.54 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2012-12-11 · Exercise / conversion · Disposed 67,200 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.16 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2012-12-11 · Exercise / conversion · Disposed 1,045 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.74 · Expires 2014-02-19 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2012-12-11 · Exercise / conversion · Disposed 2,395 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.01 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2012-12-11 · Exercise / conversion · Disposed 652 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.60 · Expires 2021-02-17 | Direct | 38,333 |
Reported balance
After 2012-12-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2012-12-11 · Exercise / conversion · Disposed 11,500 · Balance 38,333 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 248,002 |
Reported balance
After 2022-02-25 transaction · row 1
1 source rowRow 1 · 2022-02-25 · Tax withholding · Disposed 40,490 · Balance 248,002 |
CrowdStrike Holdings, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 38,724 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 68 · Balance 38,724 F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock. F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. F3: Includes shares to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock.
F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.
F3: Includes shares to be issued in connection with the vesting of one or more RSUs.
GENERAL DYNAMICS CORP
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,792 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 105 · Balance 13,792 F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2013 Filed Aug 2, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 5,634 | $32.57 | $183,510.65 |
DisclosureSEC source: 0001179110-13-012603 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2013 Filed Aug 2, 2013 21:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 774 | $32.57 | $25,210.73 |
DisclosureSEC source: 0001179110-13-012603 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 19,517 | $36.73 | $716,859.41 |
DisclosureSEC source: 0001179110-13-004011 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,784 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 15,024 | $37.58 | $564,601.92 |
DisclosureSEC source: 0001179110-13-003029 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,301 Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 145,510 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-13-003029 · edgar.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,510 Underlying: Common stock · 145,510 shares Expires 2023-02-13 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 48,504 on 02/14/2014, 48,503 on 02/14/2015, and 48,503 on 02/14/2016. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 71,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003029 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,325 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 165 | $0.00 Strike: $32.57 | $0.00 |
DisclosureSEC source: 0001179110-13-002288 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 165 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 3,611 | $0.00 Strike: $32.47 | $0.00 |
DisclosureSEC source: 0001179110-13-002288 · edgar.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,611 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 3,466 | $37.14 | $128,727.24 |
DisclosureSEC source: 0001179110-13-002288 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,095 Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 165 | $32.57 | $5,374.38 |
DisclosureSEC source: 0001179110-13-002288 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 3,611 | $32.47 | $117,242.31 |
DisclosureSEC source: 0001179110-13-002288 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,500 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 13 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,333 Underlying: Common shares · 11,500 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 652 | $0.00 Strike: $59.01 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 12 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 652 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,395 | $0.00 Strike: $52.74 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 11 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,395 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,045 | $0.00 Strike: $58.16 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 10 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,045 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 67,200 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 9 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 67,200 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 36,985 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · derivative · entry 8 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 36,985 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 119,777 | $66.00 | $7,905,282.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 7 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,338 Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,500 | $46.60 | $535,900.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 652 | $59.01 | $38,474.52 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,395 | $52.74 | $126,312.30 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,045 | $58.16 | $60,777.20 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 67,200 | $52.54 | $3,530,688.00 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 36,985 | $46.34 | $1,713,884.90 |
DisclosureSEC source: 0001179110-12-017513 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2012 Filed Dec 4, 2012 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 30,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-016882 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,338 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards will cliff vest after January 1, 2016, subject to AbbVie reaching a minimum average return on equity target for the period 2013 through 2015. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 4,011 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001179110-12-012178 · edgar.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,011 Underlying: Common shares · 4,011 shares Expires 2014-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,560 | $0.00 Strike: $52.74 | $0.00 |
DisclosureSEC source: 0001179110-12-012178 · edgar.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,395 Underlying: Common shares · 4,560 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,011 | $66.39 | $266,290.29 |
DisclosureSEC source: 0001179110-12-012178 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,583 Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,560 | $52.74 | $240,494.40 |
DisclosureSEC source: 0001179110-12-012178 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 165 | $0.00 Strike: $62.70 | $0.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · derivative · entry 24 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165 Underlying: Common shares · 165 shares Expires 2013-02-12 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,408 | $0.00 Strike: $62.70 | $0.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · derivative · entry 23 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,408 Underlying: Common shares · 6,408 shares Expires 2013-08-31 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 187 | $0.00 Strike: $50.03 | $0.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · derivative · entry 22 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 187 shares Expires 2013-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,268 | $0.00 Strike: $50.03 | $0.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · derivative · entry 21 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,268 shares Expires 2013-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,573 | $62.70 | $412,127.10 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 20 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,034 Read SEC document |
| June 19, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,455 | $50.03 | $372,973.65 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 19 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,665 | $62.76 | $230,015.40 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 18 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,152 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.76 | $37,653.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 17 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,817 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,900 | $62.75 | $181,975.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 16 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,417 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $62.75 | $125,490.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 15 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,317 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,435 | $62.74 | $215,511.90 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 14 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,317 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.74 | $6,273.75 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 13 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,752 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,700 | $62.74 | $169,384.50 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 12 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,852 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $62.73 | $62,730.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 11 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,552 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.73 | $18,817.50 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 10 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,552 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.72 | $6,272.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 9 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,852 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.72 | $6,271.50 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 8 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $62.71 | $56,434.50 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 7 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $62.70 | $62,700.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.70 | $18,808.50 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.69 | $18,807.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,252 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.